Clinical trials: Myasthenia
Spinal Muscular Atrophy, Muscular Dystrophy
National Registry for Egyptian Pediatric Neuromuscular Diseases
Our aim is to establish multi-center national Egyptian database of information for inherited and acquired neuromuscular diseases in infants and children from 0 to 18 years of age.
- Conditions
- Spinal Muscular Atrophy, Muscular Dystrophy, Muscle Diseases, Myasthenic Syndromes
- Trial name
- NCT02124616
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Ain Shams University
Thymectomy, Myasthenia Gravis
The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor
Surgery plays an important role in the treatment of anterior mediastinum disease. The major surgical approaches include: cervical approach, mid-sternal approach, cervical combined mid-sternal approach and video-assisted…
- Trial name
- 3-Hole (NCT02317224)
- Testing
- "3-Hole" subxiphorid and subcostal approach, Trans sternal approach, VATS approach
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Tang-Du Hospital
Generalized Myasthenia Gravis
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG).
- Trial name
- NCT04124965
- Testing
- Rozanolixizumab
- Where
- 43 sites in United States, Canada and 10 more
- Volunteers
- 71 people
- Sponsor
- UCB Biopharma SRL
Myasthenia Gravis
Cognitive Functioning in People With Myasthenia Graivs: Impact on Daily Life Activities, Work, Disability and Quality of Life
MYCOG primarily aims to estimate the prevalence of cognitive difficulties in patients with MG treated at Besta Institute. Secondary aims include: a) assess the degree to which cognitive difficulties are associated to work…
- Trial name
- MYCOG (NCT06718855)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Myasthenia Gravis Generalized
Markers of Favorable Response to FcRn Inhibitors(INFORM)
Myasthenia gravis is an autoimmune neurological disease caused by autoantibodies primarily directed against components of the postsynaptic membrane of the neuromuscular junction.
- Trial name
- INFORM (NCT06685055)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Myasthenia Gravis
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be…
- Trial name
- NCT06298565
- Testing
- efgartigimod
- Where
- 35 sites in United States, Austria and 4 more
- Volunteers
- 680 people
- Sponsor
- argenx
Myasthenia Gravis
Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
The primary study objective is to evaluate medium- and long-term safety of HBM9161 in combination with background treatment for gMG patients through the observation on adverse events and laboratory abnormalities during study…
- Trial name
- NCT05332210
- Testing
- HBM9161 Injection (680mg)
- Where
- China
- Volunteers
- 111 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Multiple Sclerosis, Clinically Isolated Syndrome
Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
PRISMA, is a pregnancy registry study, focused on comprehensively collecting information about pregnancy in women with chronic neurological conditions from across the United States and internationally.
- Conditions
- Multiple Sclerosis, Clinically Isolated Syndrome, NMOSD, Myasthenia Gravis
- Trial name
- NCT06940323
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Generalized Myasthenia Gravis
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
- Trial name
- NCT05556096
- Testing
- ALXN1720
- Where
- 132 sites in United States, Argentina and 20 more
- Volunteers
- 260 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Generalized Myasthenia Gravis
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
This is an open label, single arm study, to evaluate safety, tolerability and preliminary efficacy of HN2301 in patients with Generalized Myasthenia Gravis.
- Trial name
- NCT07556120
- Testing
- HN2301 injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shenzhen MagicRNA Biotechnology Co., Ltd
Myasthenia Gravis
Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis
This study examines the effect of adjuvant therapy with the oral beta-agonist Salbutamol in patients with generalized myasthenia gravis on stable standard of care having residual symptoms.
- Trial name
- BETA-MG (NCT03914638)
- Testing
- Salbutamol 4Mg Tablet
- Where
- 2 sites in Denmark
- Volunteers
- 30 people
- Sponsor
- University of Aarhus
Myasthenia Gravid
Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis
Immunomodulation is effective in treating patients with myasthenia gravis (MG), but prior studies have not adequately defined if plasma exchange (PLEX) in superior to intravenous immunoglobulin (IVIG) in the treatment of…
- Trial name
- NCT01179893
- Testing
- IVIG, PLEX
- Where
- Canada
- Volunteers
- 87 people
- Sponsor
- University Health Network, Toronto
Myasthaenia Gravis
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis.
- Trial name
- NCT06799247
- Testing
- Decartes-08
- Where
- 34 sites in United States, Canada and 6 more
- Volunteers
- 128 people
- Sponsor
- Cartesian Therapeutics
Myasthenia Gravis, MuSK MG
MuSK Myasthenia 1000 Study
The MuSK myasthenia gravis 1000 study seeks to collect saliva samples from 1000 subjects with laboratory confirmed diagnosis of MuSK myasthenia to identify genetic variations associated with MuSK MG.
- Conditions
- Myasthenia Gravis, MuSK MG, MuSK Myasthenia Gravis
- Trial name
- MuSK 1000 (NCT06259071)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- George Washington University
Lambert Eaton Myasthenic Syndrome
Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).
- Trial name
- 3 4-DAP (NCT01825395)
- Testing
- 3, 4-Diaminopyridine
- Where
- United States
- Sponsor
- University of Colorado, Denver
Myasthenia Gravis
A Prospective Cohort Study of Myasthenia Gravis in China
The goal of this prospective cohort study is to investigate long-term therapeutic strategies for myasthenia gravis (MG) and identify potential biomarkers. The main questions it aims to answer are: 1.
- Trial name
- NCT06006832
- Testing
- Steroid Drug, Withdraw all immunosuppresants
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Peking Union Medical College Hospital
Myasthenia Gravis Generalised
Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder primarily caused by antibodies targeting postsynaptic components of the neuromuscular junction, most commonly the acetylcholine receptor (AChR).
- Trial name
- PROMPT (NCT07337395)
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Myasthenia Gravis, Generalized
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
This study is a single-center, open-label, single-arm, dose-exploration study to evaluate the safety and preliminary effectiveness of BCMA CAR-T（S103） in the treatment of refractory, generalized myasthenia gravis.
- Trial name
- NCT06958939
- Testing
- Dose level 1 group, Dose level 2 group, Dose level 3 group
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ting Chang, MD
Myasthenia Gravis, MuSK, AChR Myasthenia Gravis
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Evaluate the long-term safety of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis.
- Trial name
- NCT03579966
- Testing
- Amifampridine Phosphate
- Where
- 3 sites in United States, Italy
- Volunteers
- 63 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Myasthenia Gravis
Efficacy of Methotrexate in Myasthenia Gravis
Myasthenia gravis is a rare neuromuscular disorder characterized by weakness and fatigability of ocular, bulbar, and extremity musculature.
- Trial name
- NCT00814138
- Testing
- Methotrexate
- Where
- 16 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- University of Kansas Medical Center